RBC Capital Comments on Valeant (VRX) Earnings

RBC Capital maintains Sector Perform Valeant Pharmaceuticals (NYSE: VRX).

Analyst Douglas Miehm comments to clients that his team requires more details relating to Branded Rx revenues even though most investors seem to "find comfort in the Adj. EBITDA guidance increase." He closes his mid-morning note by telling clients that he trusts VRX could "benefit from rebranding."

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $9.71 yesterday.

You May Also Be Interested In

• DA Davidson Reiterates Buy Rating on Tractor Supply Company (TSCO) Amid Soft Q2 Expectations
• Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Stifel
• ProLogis (PLD) PT Raised to $162 at Truist Securities